Anixa Biosciences
ANIX
11 hedge funds and large institutions have $385K invested in Anixa Biosciences in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.05% more ownership
Funds ownership: 1.43% → 1.48% (+0.05%)
15% less funds holding
Funds holding: 13 → 11 (-2)
43% less capital invested
Capital invested by funds: $673K → $385K (-$288K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20.7K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$8.02K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.2K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$2K |
ANIX Hedge Fund Activity: Q1 2017 in Review
11 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q1 2017, worth a combined $385K — down 43% from $673K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ANIX and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was BlackRock, opening a new position worth an estimated $20.7K. The largest seller was UBS Group, cutting an estimated $3.2K.
- 11 institutional investors held Anixa Biosciences (ANIX) as of Q1 2017, down from 13 in Q4 2016.
- Funds reported $385K of Anixa Biosciences stock for Q1 2017, down 43% quarter-over-quarter.
- 1 fund opened new Anixa Biosciences positions in Q1 2017 and 2 closed out, a net change of -1 holder.
- The largest Anixa Biosciences buyer in Q1 2017 was BlackRock, an estimated $20.7K added.
- The largest Anixa Biosciences seller in Q1 2017 was UBS Group, an estimated $3.2K sold.
Based on aggregated 13F filings for Q1 2017.